Asciminib single agent

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Phase 2

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

RecruitingNCT07354074

Novartis PharmaceuticalsChronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Start: 2026-04-28End: 2033-02-23Target: 50Updated: 2026-09-02

Phase 4

Asciminib Roll-over Study

RecruitingNCT04877522

Novartis PharmaceuticalsChronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Start: 2022-08-30End: 2030-08-30Target: 347Updated: 2026-07-06

Related Papers

ASC4Kids-2: Asciminib in pediatric chronic myeloid leukemia with or without T315I.

Journal of Clinical Oncology2026-05-28